SELLAS Life Sciences Group, Inc.
SLS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001390478
No open-market purchases or sales by SELLAS Life Sciences Group, Inc. insiders were filed in the last 90 days; 193 institutions reported holding it in 13F filings for Q2 2026, worth $1.08B in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding SELLAS Life Sciences Group, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 28 | 1 | 29 | +2 |
| Shares | 2.19M | 308.5K | 1.89M | +10.7K (+0.6%) |
| Value | $4.42M | $623.0K | $4.46M | +$661.3K (+17.4%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (9)
Institutions that held SELLAS Life Sciences Group, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Dimensional Fund Advisors LP | 58,592 | $138.0K | 0.00% |
| XTX Topco Ltd | 55,403 | $130.8K | 0.03% |
| Opus Capital Group, LLC | 19,672 | $46.0K | 0.01% |
| Virtu Financial LLC | 18,379 | $43.0K | 0.01% |
| Two Sigma Securities, LLC | 16,076 | $37.9K | 0.01% |
| Citigroup Inc | 100 | $236 | 0.00% |
| NewSquare Capital LLC | 100 | $236 | 0.00% |
| Bank of America Corp | 48 | $114 | 0.00% |
| Godsey & Gibb Associates | 4 | $9 | 0.00% |
Sold out (7)
Institutions that held SELLAS Life Sciences Group, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Highbridge Capital Management LLC | 100,000 | $202.0K |
| Two Sigma Investments, LP | 53,685 | $108.0K |
| Renaissance Technologies LLC | 22,400 | $45.0K |
| JPMorgan Chase & Co | 3,550 | $7.00K |
| CWM, LLC | 2,000 | $4.00K |
| UBS Group AG | 1,359 | $3.00K |
| Simplex Trading, LLC | 1,315 | $2.00K |
Not filed for Q4 2022 yet (1)
Institutions that held SELLAS Life Sciences Group, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Empery Asset Management, LP | 308,466 | $623.0K |